Certara has struck a deal to scoop up Simcyp, a maker of modeling software for preclinical drug research, in a move that expands the breath of its technology offerings to drug developers. The deal is valued at $32 million, the St. Louis Business Journal reported.
St. Louis-based Certara--which was formed through the merger of scientific software providers Tripos and Pharsight--indicated that U.K.-based Simcyp's operations will stay intact. The buyout will enable Certara to offer its biopharma customers Simcyp's software for predicting drug-to-drug interactions in virtual patient populations, including kids, Certara said in a release.
Closely held Certara said that the buyout builds on the company's Tripos software used in drug discovery and its Pharsight solution for users conducting preclinical and clinical drug research. In general, providers of scientific software such as PerkinElmer ($PKI) and Accelrys ($ACCL) have been buying up smaller competitors to broaden their offerings.
"From a translational science perspective, Simcyp's preclinical simulation technologies, which include prediction of drug/drug interactions, fit perfectly between Certara's existing discovery and clinical research offerings, thus enabling an end-to-end solution," Certara CEO Jim Hopkins said in a statement.
- here's the release
- see the St. Louis Business Journal's report